NEW YORK, July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston, July 25 - 27, 2023. Actinium will present "Targeted Radiotherapeutics & Innovative Combinations to Alter the Treatment Outcome for Conditioning, Hematological & Solid Tumor Malignancies" on Thursday, July 27, 2023 at 12:30pm ET.

About Actinium Pharmaceuticals, Inc.

Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies.  Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes.  Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.

For more information, please visit: https://www.actiniumpharma.com/

Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-to-present-at-the-2nd-annual-targeted-radiopharmaceuticals-summit-301883264.html

SOURCE Actinium Pharmaceuticals, Inc.